Drug intelligence / Profile preview

everolimus + mitomycin C

Development stage: Unknown
Lead developer: Novartis
Modality: Small Molecules
Administration: Oral, Intravenous

Overview

A combination therapy consisting of everolimus (RAD001), an mTOR inhibitor, and mitomycin C, an antibiotic with antineoplastic properties. This combination has been studied in clinical trials for treating various cancers, particularly metastatic esophagogastric cancer. In a phase I trial for metastatic esophagogastric cancer, it showed encouraging signs of antitumor activity. The recommended dose from phase I trials was everolimus 10 mg/day combined with intravenous mitomycin C 5 mg/m² every 3 weeks.

Brand names: AfinitorZortressMutamycin
Other names: RAD001 + Mitomycin CRAD001 + MitomycinC

Targets

TXNRD2 (Thioredoxin reductase 2)Mechanistic target of rapamycin kinase complex 2Mechanistic target of rapamycin complex 1DNA

Beyond the preview

Go deeper on everolimus + mitomycin C.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on everolimus + mitomycin C.

Explore the full profile